Company Profile

Chimerix, Inc. is a biopharmaceutical company. The Companyâ€™s advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. It is conducting phase I dose escalation studies of ONC206 to evaluate safety and PK data. The second-generation imipridone (ONC206) is in dose-escalating clinical trials for adult and pediatric patients with primary central nervous system tumors. Its other product candidates include ONC212 and CMX521. ONC212 is an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. CMX521 is a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. CMX521 is not mutagenic, clastogenic, or associated with mitochondrial toxicity. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides. This library includes approximately 3,500 nucleoside analog compounds. It is a wholly owned subsidiary of Jazz Pharmaceuticals plc.

Employees

Sector

Biotechnology & Medical Research

More about the company

22/04/25	Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix	MT
22/04/25	Chimerix, Inc. Announces Alan Campion as the Chief Financial Officer	CI
22/04/25	Chimerix, Inc. Terminates the Amended and Restated Loan and Security Agreement	CI
22/04/25	Chimerix, Inc. Announces Board Changes	CI
21/04/25	Chimerix, Inc.(NasdaqGM:CMRX) dropped from NASDAQ Composite Index	CI
21/04/25	Jazz Pharmaceuticals plc completed the acquisition of Chimerix, Inc..	CI
21/04/25	Chimerix, Inc.(NasdaqGM:CMRX) dropped from S&P TMI Index	CI
21/03/25	Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
06/03/25	Health Care Stocks Rise -- Health Care Roundup	DJ
06/03/25	Deals of the day-Mergers and acquisitions	RE
06/03/25	Jefferies Downgrades Chimerix to Hold From Buy, Price Target is $8.50	MT
05/03/25	Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says	MT
05/03/25	Deals of the day-Mergers and acquisitions	RE

06/03/25	Jefferies Downgrades Chimerix to Hold From Buy, Price Target is $8.50	MT
05/03/25	Wedbush Downgrades Chimerix to Neutral From Outperform, Adjusts Price Target to $8.55 From $7	MT
18/02/25	Wedbush Adjusts Price Target on Chimerix to $7 From $6, Keeps Outperform Rating	MT
23/05/23	Baird Initiates Chimerix at Outperform With $7 Price Target	MT
07/09/22	Capital One Starts Chimerix at Overweight With $7 Price Target	MT

24/03/25	Chimerix Reports Fourth Quarter and Year End 2024 Financial Results	AQ
21/03/25	Chimerix: Q4 Earnings Snapshot	AQ
21/03/25	Chimerix Reports Fourth Quarter and Year End 2024 Financial Results	AQ
11/03/25	CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX	BU
11/03/25	Chimerix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ

29/12/15	Wall Street fléchit dans le sillage des valeurs de l'énergie
29/12/15	Apple : Wall Street fléchit dans le sillage des valeurs de l'énergie
29/12/15	Wall Street fléchit dans le sillage des valeurs de l'énergie
28/12/15	Chimerix : Wall Street ouvre en baisse avec le pétrole
28/12/15	Wall Street ouvre en baisse avec le pétrole

3 years	0.75	8.55
5 years	0.75	8.55
10 years	0.75	11.57

Chimerix, Inc. Stock

Stocks

CMRX

US16934W1062

Biotechnology & Medical Research

Latest news: Chimerix, Inc.

Analysts' recommendations: Chimerix, Inc.

Press Releases: Chimerix, Inc.

News in other languages: Chimerix, Inc.

Quotes and Performance

Price Extremes

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/4/25	Michelle LaSpaluto	Issuer sale	Chief Financial Officer	1,015,869	1.1295%
21/4/25	Martha Demski	Issuer sale	Chairman	393,055	0.4370%
21/4/25	Fred Middleton	Issuer sale	Director	631,523	0.7022%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHIMERIX, INC.	-0.12%	-.--%	-	-	801M
WUXI APPTEC CO., LTD.	+1.52%	-7.16%	+51.66%	+67.41%	65B
LONZA GROUP AG	+1.52%	+7.17%	+10.77%	+77.89%	51.2B
ARGENX SE	+0.30%	+0.19%	+2.53%	+56.14%	51.19B
IQVIA HOLDINGS INC.	-0.38%	+1.40%	+25.39%	+42.37%	43.93B
BEONE MEDICINES AG	+0.30%	+5.64%	+16.19%	+133.30%	41.96B
REVOLUTION MEDICINES, INC.	+2.35%	-6.08%	+237.25%	+528.10%	38.14B
CELLTRION, INC.	+2.16%	+10.36%	+18.92%	+59.70%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+37.09%	+1.80%	25.2B
GENMAB A/S	+1.60%	+3.97%	+21.34%	+22.33%	22.5B
Average	+0.80%	+0.14%	+46.79%	+109.89%	41.37B
Weighted average by Cap.	+0.92%	+0.04%	+45.46%	+111.11%